Enzalutamide & 5-year survival in mHSPC.

[pca2004]

More from ASCO 2023 [1] [2].

"Patients in the ENZAMET trial (n = 1125) were randomized 1:1 to arm A, the control arm consisting of TS plus a standard non-steroidal antiandrogen ([NSAA] bicalutamide, nilutamide, or flutamide), or enzalutamide at 160 mg per day plus TS in arm B. "

"The 5-year OS rates were 81% and 66% for those with low-volume mHSPC who did not receive docetaxel with enzalutamide and NSAA treatment, respectively, and 57% and 47% for those with high volume."

-Patrick

[1] urologytimes.com/view/enzal...

[2] urologytimes.com/view/dr-ia...

[pca2004]

see also: urologytimes.com/view/clini...

[pca2004 in reply to pca2004]

Apologies - this was from 2022.

[cigafred]

TS=testosterone suppression